Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how custodial cash turns into revenue—and how shifting healthcare policy may impact it—means wading through dense HealthEquity reports. Each 10-K details millions in HSA assets, while every 8-K discloses new bank partnerships and acquisition costs. If you have ever searched for “HealthEquity insider trading Form 4 transactions” or tried to map service-fee trends across quarters, you know the challenge.
Stock Titan solves it. Our AI reads every HealthEquity quarterly earnings report 10-Q filing and highlights interchange income, member growth, and segment margins in plain English. Form 4 alerts surface HealthEquity Form 4 insider transactions real-time, so you can monitor executive activity without refreshing EDGAR. Need deeper context? Click any headline for concise notes that make HealthEquity SEC filings explained simply—no more scrolling through footnotes.
Whether you are comparing custodial spread in the HealthEquity annual report 10-K simplified, analysing CEO pay via the HealthEquity proxy statement executive compensation, or following surprise announcements with HealthEquity 8-K material events explained, our platform keeps every disclosure in one place. Practical use cases include: spotting HSA asset inflows before earnings, tracking regulatory risk language shift, and reviewing HealthEquity executive stock transactions Form 4 before material events. From HealthEquity earnings report filing analysis to understanding HealthEquity SEC documents with AI, all forms update instantly—giving you a head start on the numbers that drive this consumer-directed benefits leader.
HealthEquity (NASDAQ:HQY) filed an 8-K disclosing results of its 26 June 2025 annual meeting and a significant capital-return action.
Shareholder votes: All nine directors were re-elected; PricewaterhouseCoopers LLP was ratified as auditor (82,962,314 for, 346,165 against); and FY-25 executive compensation was approved on an advisory basis (76,093,619 for, 3,218,477 against).
Capital allocation: The board authorized a new $300 million share-repurchase program, supplementing the existing $300 million authorization from August 2024. Repurchases may occur through open-market or privately negotiated transactions, including Rule 10b5-1 plans, and can be suspended at any time.
No other material disclosures were made.
FAQ
What is the current stock price of Healthequity (HQY)?
What is the market cap of Healthequity (HQY)?
What primary services does HealthEquity Inc provide?
How does HealthEquity differ from other benefits administration companies?
How does the company ensure the security of its managed funds?
What role does technology play at HealthEquity?
Who are HealthEquity’s key partners?
What educational resources does the company offer for benefit management?
How does HealthEquity support employers in managing benefits costs?
What factors contribute to HealthEquity's reputation for trust and expertise?
